Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Maintenance After ASCT in PCNSL
NCT05334238Phase 3Unknown
- Sponsor
- Ruijin Hospital
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05334238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334238.